PSMA PET Scan and mpMRI for Prostate Cancer Detection

Sponsor: VA Greater Los Angeles Healthcare System

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05820724

Patient View

This phase 2 trial evaluates if adding PSMA PET to mpMRI enhances prostate cancer detection. Eligible patients with PI-RADS 4-5 lesions on mpMRI will be randomized to receive either DCFPyL PET/CT imaging or no PSMA PET before biopsy. The PSMA group will have biopsy targets based on combined imaging findings, while the control group relies on mpMRI alone.

Patient Parameters

Program Overview

Prospective, randomized, phase 2 clinical trial to determine if PSMA PET imaging plus mpMRI improves detection of clinically significant prostate cancer as compared to mpMRI alone.

Description

This a prospective, randomized, phase 2 clinical trial. We will enroll patients who underwent mpMRI of the prostate as part of their standard clinical care, have PI-RADS 4, or 5 lesion(s) on mpMRI, and are scheduled to undergo fusion guided prostate biopsy. Subjects that sign the consent form will be randomized to undergo DCFPyL PET/CT imaging or no PSMA PET imaging prior to the prostate biopsy. In the PSMA scan cohort, decision for biopsy targets will be made based on the combination of the findings of mpMRI and PSMA scans. In the no PSMA scan (control) group, the biopsy will be performed based on mpMRI findings. Each patient will undergo 12 core systematic biopsy as the standard of care. Two additional biopsies for each mpMRI and PSMA PET and overlap lesion will also performed.

Eligibility Criteria

Inclusion Criteria

  • Patients with PI-RADS 4-5 lesion(s) on mpMRI and have elected to undergo a prostate biopsy
  • Prostate mpMRI completed within 9 months prior to enrollment
  • Patient capable of providing written informed consent
  • Patient willing to be randomized to prostate mpMRI only vs prostate mpMRI + DCFPyL PET/CT

Exclusion Criteria

  • Less than 18 years-old at the time of radiotracer administration
  • Medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study procedures or compliance.
  • Creatinine clearance exceeding institutional requirements for prostate mpMRI

Get This Program In Your Inbox

You can sign up and apply your patients for this program.